Screening for peptides targeted to IL-7Rα for molecular imaging of rheumatoid arthritis synovium
Arthritis Research & Therapy volume 18, Article number: 230 (2016)
Interleukin-7 receptor alpha (IL-7Rα) represents a biomarker with potential applications in rheumatoid arthritis (RA) diagnosis and therapy. We have therefore searched by phage display potential IL-7Rα specific peptides with the primary goal being to develop in vivo molecular imaging tools.
IL-7Rα-targeted peptides were searched within a disulfide-constrained combinatorial phage displayed library of random linear heptapeptides. The apparent dissociation constant (Kd) and half maximal inhibition constant (IC50) were estimated for phage clones and synthesized peptides by ELISA. We used 5-Aza-2’-deoxycytidine (ADC)-stimulated Jurkat cells and human synovial tissue from patients with RA for in vitro characterization of peptides. For molecular imaging studies performed by magnetic resonance imaging (MRI), experimental arthritis was induced in DBA/1 male mice by immunization with an emulsion of complete Freund’s adjuvant and type II collagen from chicken sternal cartilage.
After several steps of phage display and peptide screening, two IL-7Rα-specific heptapeptides (P258 and P725) were selected from the initial library, based on their affinity for the target (extracellular domain of IL-7Rα, which contains a fibronectin type III repeat-like sequence). P258 (a linear peptide obtained by removing the Cys-constraint) had the lowest affinity for fibronectin itself and was therefore proposed for molecular imaging. After grafting to ultra-small superparamagnetic particles of iron oxide (USPIO), P258 produced a strong negative contrast on MRI in mice with collagen-induced arthritis (CIA), even at 2 hours post injection. The co-localization of USPIO-P258 with IL-7Rα-expressing cells in the synovial tissue from CIA mice and its ability to discriminate the level of IL-7R expression and the disease severity confirmed its efficacy as an in vivo IL-7Rα imaging agent. Interestingly, the cyclic peptide (P725), which was less adequate for molecular imaging because of higher affinity for fibronectin, had a strong ability to compete with IL-7 for the IL-7Rα binding sites, making it a potential candidate for blocking applications. Accordingly, P725 prevented the signal transducer and activator of transcription 5 (STAT5) activation induced by IL-7 in ADC-stimulated Jurkat cells.
The two peptides identified in this work demonstrate that IL-7Rα targeting in RA presents potential applications for in vivo molecular imaging and putative blocking purposes.
Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease that causes joint damage, decreased quality of life and cardiovascular complications, among other comorbidities. With 5–50 per 100,000 new cases annually, RA occurs in 0.5–1 % of adults in industrialized countries, being more frequent in women and elderly people .
Interleukin-7 (IL-7) is an anti-apoptotic cytokine, essential for T cell proliferation, development and homeostasis. It is also involved in B cell development. The IL-7 receptor (IL-7R) comprises two heterodimeric subunits, IL-7Rα and the common γ-chain (γc) respectively. IL-7Rα is composed of a 195 amino acid intracellular domain, a 25 amino acid transmembrane domain and an extracellular region comprising 219 amino acids. Four invariant cysteine residues located at the N-terminus of the extracellular domain are involved in intrachain disulfide bond formation. A Trp-Ser-X-Trp-Ser (WSXWS) motif is located close to the transmembrane domain of the extracellular region of IL-7Rα, which also contains a fibronectin (FN) type III-like domain. The intracellular domain of IL-7Rα is responsible of signal transduction via the recruitment of signal transducing molecules, such as the Janus kinase 1 (Jak1), the signal transducer and activator of transcription 5 (STAT5) and the src family of tyrosine kinases, and is involved in the IL-7-dependent activation of phosphatidylinositol 3-kinase (PI3K) [2, 3]. IL-7 binding to its receptor triggers several signaling cascades, i.e., Jak/STAT, PI3K, Ras and mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK), being essential for lymphocyte survival, homeostasis and differentiation [2–4].
IL-7 and IL-7R are over-expressed in the RA synovium. IL-7 plays a crucial role in T cell activation and osteoclastogenesis by upregulating T cell-derived cytokines, including the receptor activator of nuclear factor-κB ligand (RANKL) . In RA synovitis, not only T cells, but also synovial macrophages and fibroblasts over-express IL-7Rα, thereby making IL-7Rα the transcript most differentially expressed between RA and other inflammatory joint conditions such as osteoarthritis, systemic lupus erythematosus, psoriatic arthritis and gout [6–8]. Synovial fibroblasts also produce a high quantity of soluble IL-7Rα subsequent to their stimulation by cytokines such as tumor necrosis factor-α (TNFα), IL-1 and IL-17 [9–11]. According to several observations, soluble IL-7Rα stabilizes IL-7 and amplifies its T cell stimulatory effects . The increased expression and high serum concentrations of soluble IL-7Rα is associated with poor response to anti-TNFα therapy in patients with RA [13, 14]. The pathogenic role of the IL-7/IL-7R axis in RA is further illustrated in a mouse model of the disease (collagen-induced arthritis, CIA), in which both IL-7 or IL-7R blockade using monoclonal antibodies results in significant improvements in disease activity [15–17]. Of note, recent observations also highlight the potential involvement of IL-7/IL-7R in other autoimmune disorders, such as systemic lupus erythematosus and Sjögren’s syndrome [18, 19].
As it is currently an incurable disease, diagnosis and treatment of RA before its progression towards a debilitating stage is imperative for patients. Magnetic resonance imaging (MRI) is reported to be the best clinical imaging technique for the diagnosis of RA, allowing observation of the characteristic inflammation and lesions that are not adequately displayed using conventional radiography. Molecular imaging of specific pathological processes in synovitis would increase the likelihood of early diagnosis, disease staging and monitoring. Any of the molecular actors involved in chronic inflammation, cell proliferation and apoptosis represents putative targets for functionalized imaging probes, thus optimizing the diagnostic capability of clinical imaging techniques [20–23].
Our work is integrated within this clinical and scientific context, by trying to develop molecular tools to image IL-7Rα in vivo as a diagnostic biomarker, and as a marker of response to RA therapy. To achieve this goal, a randomized cyclic heptapeptide phage display library was screened against IL-7Rα, leading to the identification of two peptides specific to this biomarker, one of them being a putative blocking agent for IL-7 (called P725). The peptides were characterized in terms of affinity, biologic activity and diagnostic potential by MRI. The peptide dedicated to MRI applications (called P258) was coupled to ultra-small superparamagnetic particles of iron oxide (USPIO, an MRI contrast agent producing a negative contrast) and its pharmacokinetics, biodistribution and diagnostic potential were evaluated in mice. USPIO present a particular interest for molecular imaging due to their excellent MRI efficacy, biocompatibility and biodegradability. The blood half-life of this material is significantly prolonged by coating it with hydrophilic polymers, such as poly(ethylene glycol) (PEG), which reduce its opsonization and the clearance by the reticuloendothelial system, thus improving the targeting of specific biomarkers [24, 25]. The vectorizing peptide P258 and PEG used as a coating material were covalently coupled to the carboxyl groups exposed at the surface of USPIO.
The experiment of phage display and characterization of the candidate phage clones
Phage display library and Escherichia coli host strain
IL-7Rα-targeted peptides were searched within a disulfide-constrained combinatorial library of random linear heptapeptides fused to the minor coat protein (pIII) of M13 bacteriophage (Ph.D.-C7C™ phage display library, New England BioLabs® Inc., Westburg b.v., Leusden, The Netherlands). The E.coli host ER2738 (E. coli K12 ER2738, F+, tetracycline-resistant strain; New England BioLabs®) was used for phage amplification and clone isolation.
The panning of phage display library against IL-7Rα
The phage display library was panned against recombinant human IL-7 Rα/Fc chimera (R&D Systems, Abingdon, UK), which was immobilized alternatively on Dynabeads® Protein A or G (Invitrogen Dynal, Merelbeke, Belgium) during the four rounds of biopanning. To increase the peptide specificity and stringency, the target concentration was diminished from 100 nM to 75 nM during the panning rounds; Dynabeads Protein A/Protein G were alternated at each round of panning; the incubation time with the target was reduced stepwise; the incubation times with blocking or related proteins (BSA, Fc-IgG (human IgG, Fc fragment from plasma, Calbiochem, VWR, Leuven, Belgium), fragment 3 of recombinant human FN-1 (R&D Systems)) were increased stepwise, and the Tween-20 concentration was increased at each panning round (i.e., 0.1–0.5 %) in the incubation and rinsing buffer (phosphate-buffered saline, PBS; per liter: 8 g NaCl, 0.2 g KCl, 2.31 g Na2HPO4 × 12 H2O, 0.2 g KH2PO4, pH 7.4). The detailed bio-panning protocol is available in Additional file 1: Methods.
Evaluation of the affinity of the phage clones for IL-7Rα
For affinity tests, IL-7Rα was diluted at a concentration of 10 μg/mL in 0.1 M NaHCO3, pH 8.6, and immobilized overnight at 4 °C. The control wells were coated with 5 mg/mL of BSA or with 10 μg/mL of FN and used to evaluate the phage non-specific binding. Phages were diluted in PBS supplemented with 0.5 % Tween-20 (PBST), and were incubated with both test and control wells (2 h, 37 °C). Bound phages were detected with horseradish peroxidase (HRP)-conjugated anti-M13 antibody (Amersham Pharmacia Biotech Benelux, Roosendaal, The Netherlands) diluted 1:5000 in THBS completed with 5 mg BSA/mL. The staining reaction was developed with 2,2´-Azino-bis(3-Ethylbenzothiazoline-6-sulfonic acid) (ABTS), diamonium salt (Sigma-Aldrich, Bornem, Belgium) solution completed with 0.05 % H2O2. The optical density (OD)405 was measured using a microplate reader (StatFax-2100, Awareness Technology, Fisher Bioblock Scientific, Tournai, Belgium).
To confirm the binding specificity of three selected clones, immobilized IL-7Rα was pre-incubated with a range of human recombinant IL-7 (R&D Systems) concentrations. The phages were added 30 minutes later at a concentration equal to their apparent dissociation constant (K*d) and the incubation was continued for one more hour. Phages bound to the target were detected with HRP-conjugated anti-M13 antibody as described above. The affinity tests are additionally described in Additional file 1: Methods.
Sequencing of the phage clones
Phage DNA was isolated and purified by phenol extraction–ethanol precipitation. The sequence reaction (Mastercycler Personal) was carried out by the Sanger method, using the Quick Start Kit (Beckman CoulterTM, Analis, Namur, Belgium) and a 20-base primer (5’-CCCTCATAGTTAGCGTAACG-3’) (New England Biolabs). Sequence reading was performed with JaMBW 1.1 software (http://bioinformatics.org/JaMBW/), and peptide sequences were aligned with the basic local alignment search tool (BLAST).
Characterization of the selected IL-7Rα-binding peptides
Three peptides were selected for synthesis and subsequent evaluation. They were synthesized as biotinylated or not biotinylated 8-amino-3,6-dioxaoctanoyl derivatives and encoded as follows: P722 (clone 36/R2: C-PHPQRPA-C), P725 (clone C29/R3: C-KIMKSMP-C) and P726 (clone C37/R2: C-ASACPPH-C). Peptide 726 was also synthetized in a linear version (ASACPPH) and was encoded as P258.
Estimation of the apparent dissociation constant (K*d)
Serial dilutions of biotinylated peptides were incubated with IL-7Rα or FN immobilized on ELISA plates as described above and blocked with protein-free blocking buffer (PFBB) (Perbioscience, Erembodegem, Belgium). Peptides bound to the target were detected with a goat anti-biotin antibody, followed by a peroxidase-conjugated anti-goat antibody made in horse (both from Vector Labconsult, Brussels, Belgium). The staining reaction was developed with ABTS/H2O2, and OD405 was measured with a microplate reader. The protocol is largely described in Additional file 1: Methods.
Estimation of the half maximal inhibitory concentration (IC50)
The K*d of IL-7 was determined by incubating a range of IL-7 concentrations with immobilized IL-7Rα. The bound IL-7 was then detected with a polyclonal goat anti-human IL-7 antibody (R&D Systems) followed by a horse anti-goat antibody coupled to HRP (Vector Labconsult). To estimate the IC50 of peptides, they were pre-incubated with IL-7Rα-coated wells in a range of concentrations; IL-7 was then added at a concentration equal to its K*d and the incubation continued for another 90 minutes. IL-7 bound to the target was detected as described. The detailed protocol is available in Additional file 1: Methods.
Binding of peptides to Jurkat cells and co-localization with IL-7Rα by immunofluorescence
Jurkat cells were cultured in RPMI-1640 culture medium supplemented with 10 % newborn calf serum heat-inactivated and 1 % antibiotic-antimycotic (all from Invitrogen). The cells were stimulated with 0.4 μM of 5-Aza-2’-deoxycytidine (ADC, Sigma-Aldrich) . The stimulated cells were immobilized on poly-L-lysine (Sigma-Aldrich) coated coverslips and fixed in a solution of 4 % formaldehyde (Sigma-Aldrich). After blocking the cells with PFBB, they were co-incubated with mouse anti-human IL-7Rα monoclonal antibody (Sigma-Aldrich) and biotinylated peptides P258 (0.04 μM) or P725 (5 μM). Biotinylated peptides were detected with a goat anti-biotin antibody followed by fluorescein-conjugated rabbit anti-goat antibody (both from Vector Labconsult). Anti-IL-7Rα antibody was detected with Texas Red horse anti-mouse antibody (Vector Labconsult). Control samples consisted of ADC-stimulated or non-stimulated (NS) Jurkat cells incubated with low-affinity peptide binders (e.g., P255, P259), a mouse IgG isotype control, or with secondary antibodies after excluding the primary antibodies. The coverslips were mounted on slides with Vectashield mounting medium for fluorescence with 4',6-diamidino-2-phenylindole (DAPI) (Vector Labconsult) and observed on a DM2000 Leica microscope equipped with a DFC 425C camera (Leica Microsystems, Groot Bijgaarden, Belgium). The protocol is additionally described in Additional file 1: Methods.
Immunohistochemical detection of biotinylated P258 and of IL-7Rα in knee biopsy samples from patients with RA
Synovial knee biopsies were obtained by needle arthroscopy in three untreated patients with active RA. Fresh biopsy samples (between four and six per patient) were fixed overnight in 10 % formalin buffer at pH 7.0 and embedded in paraffin. Sections of 5 μm thickness were cut and treated to remove paraffin (two baths of toluene for 10 minutes each) and rehydrate them (three baths of 95 % ethanol for 10 minutes each, followed by 10 minutes in running cold tap water and 5 minutes in distilled water), followed by unmasking of epitopes in a citrate solution according to standard procedures. The endogenous peroxidases were blocked with 0.3 % H2O2 in PBS and the non-specific epitopes were blocked with PFBB.
The tissue sections were incubated with mouse anti-human IL-7Rα monoclonal antibody (Sigma-Aldrich), followed by a peroxidase-conjugated monoclonal anti-mouse antibody produced in goat (Sigma-Aldrich). The sections were then stained with 0.05 % 3,3'-diaminobenzidine (DAB) completed with 0.02 % H2O2 in PBS. Finally, they were counterstained with Hemalun and Luxol fast blue and mounted in a permanent medium.
Endogenous biotin was blocked with a blocking kit (Invitrogen) before incubating the histologic sections with 1 μM of P258 (or with control peptides P255 and P259), followed by a goat anti-biotin antibody and a peroxidase-conjugated anti-goat antibody made in horse (both from Vector Labconsult). The staining and counterstaining were performed as described for anti-IL-7Rα monoclonal antibody. Additional information is available in Additional file 1: Methods. The study was approved by the Ethical Committee of the Université Catholique de Louvain, and informed consent was obtained from all patients.
Phospho-STAT5 detection on Jurkat cells and modulation by peptide P725
The experiment was performed in triplicate on ADC stimulated and NS cells distributed in several culture tubes treated with different compounds diluted in the culture medium as follows: (A) cells treated for 48 h with IL-7 (eBioscience, Vienne, Austria); (B) cells pre-incubated for 30 min with P725; (C) cells pre-incubated for 30 min with mouse anti-human IL-7Rα monoclonal antibody (Sigma-Aldrich). IL-7 was then added in samples B and C, and incubation continued for 48 h. The solutions were replaced every day after culture tube centrifugation and supernatant removal.
The treated cells were rinsed and immobilized on poly-L-lysine-coated coverslips. They were fixed with 4 % formaldehyde and 100 % methanol, and then blocked with a solution of 5 % normal goat serum and 0.3 % Triton X-100 prepared in PBS. Subsequently, the cells were co-incubated with human Phospho-STAT5 (Tyr694 D47E7 XP®) antibody made in rabbit and anti-Pan-keratin (C11) antibody made in mouse (both from Bioké, Leiden, The Netherlands). The cells were subsequently co-incubated with fluorescein-conjugated goat anti-rabbit antibody and horse Texas Red-conjugated anti-mouse antibody (both from Vector Labconsult). The coverslips were finally mounted on slides with Vectashield mounting medium for fluorescence with DAPI (Vector Labconsult). Detailed protocols are available in Additional file 1: Methods.
The signal intensity (SI) was measured on microphotographs corresponding to three to six different microscopic fields using the ImageJ software (National Institutes of Health, USA), and the relative ratio of fluorescent labeling (RRFL) was then calculated using the subsequent equation:
Evaluation of the lysosome content of Jurkat cells
For lysosome tracking, Jurkat cells stimulated and treated as described above were incubated with a solution of Hoechst 33342 (for nuclei staining), followed by Lysotracker® Red DND-99 (Image-mITT LIVE lysosomal and nuclear labeling kit, Life technologies, Merelbeke, Belgium). The cells were then mounted between microscope slides and coverslips, observed under a microscope and the RRFL was evaluated as described above . The protocol is additionally described in Additional file 1: Methods.
Preparation and characterization of the imaging probe
Synthesis and characterization of USPIO-P258
Peptide P258 was synthesized by the company PolyPeptide (Strasbourg, France) as an 8-amino-3,6-dioxaoctanoyl (two PEG units, used as linker) derivative (PolyPeptide, Strasbourg, France), the C-terminus of the peptide being amidated. It was then covalently conjugated to USPIO as previously described . The vectorized nanoparticles (USPIO-P258) were rendered stealth by a PEG coat, which was also used to prepare the non-specific nanoparticles (USPIO-PEG). The transverse relaxivity, r2, evaluated at 37 °C and 60 MHz in mouse blood plasma was of 98.94 s−1mM−1 for USPIO-P258 and of 107.75 s−1mM−1 for USPIO-PEG. The hydrodynamic diameter of USPIO-P258 was measured by photon correlation spectroscopy (PCS, Brookhaven system BI-160 (New York, USA) equipped with a He-Ne laser (=633 nm, 35 mW)) after 2 h of incubation at room temperature in water (48 nm), PBS (40 nm) and RPMI culture medium (37 nm).
The K*d of USPIO-P258 for the binding to IL-7Rα was determined by ELISA, using a rabbit anti-PEG monoclonal antibody (Abcam, Cambridge, UK), biotinylated goat anti-rabbit IgG and Vectastain ABC kit (both from Vector Labconsult) as previously described ; the IC50 of USPIO-P258 was evaluated using the same method as that described previously. The eventual cytotoxic effects of USPIO-P258 were determined on HepaRG™ cell line (Life Technologies) using the MTT assay (in vitro toxicology assay kit MTT-based, Sigma-Aldrich) as previously described .
Evaluation of USPIO-P258 binding to Jurkat cells
ADC-stimulated or NS Jurkat cells were incubated (n = 3/experimental group) with USPIO-P258 or USPIO-PEG at an iron concentration of 1–3 mM. The cells were subsequently rinsed and mineralized in acidic conditions, and iron concentration in cell samples was determined by relaxometry on a Bruker Minispec Mq60 (Karlsruhe, Germany) based on a calibration curve. For magnetic resonance imaging (MRI) analysis and the measurement of the transverse relaxation time (T2), the cells incubated with contrast agents were suspended in 2 % gelatin prepared in PBS. The MR images were acquired on a 300 MHz (7 T) Bruker Biospec imaging system (Ettlingen, Germany). A T2-weighted Rapid Acquisition with Relaxation Enhancement (RARE) sequence was used for cell visualization. The T2 was measured with a Multi-Slice-Multi-Echo (MSME) sequence. The results were expressed as transverse relaxation rates (R2 = 1/T2) normalized to gelatin (R2 Norm) and measured in s−1.
USPIO-P258 was co-localized with IL-7Rα expressed by Jurkat cells using an immunofluorescence protocol. At the end of the MRI studies, the cells were recovered from gelatin, resuspended in PBS and immobilized on poly-L-lysine coated coverslips, before being fixed and blocked as described previously. The cells were then co-incubated with mouse anti-human IL-7Rα monoclonal antibody (Sigma-Aldrich) and with rabbit monoclonal anti-PEG antibody (Bio-Connect/Epitomics, Huissen, The Netherlands). The cells were subsequently co-incubated with Texas Red horse anti-mouse antibody and fluorescein goat anti-rabbit antibody (both from Vector Labconsult). The coverslips were finally mounted on slides with a mounting medium for fluorescence (Vector Labconsult). The RRFL was evaluated as described above. The protocols are detailed in Additional file 1: Methods.
Evaluation of pharmacokinetic parameters, biodistribution and diagnostic ability of USPIO-P258 by molecular imaging
The experiments performed on animals were approved by the Ethics Committee of the University of Mons and they comply with the Directive 2010/63/EU. For pharmacokinetics and biodistribution evaluation, NMRI mice (n = 3 per time point; Harlan, Horst, The Netherlands) were injected with USPIO-P258 at 100 μmol Fe/kg body weight (b.w.). The pharmacokinetics and biodistribution of USPIO-PEG, used as a control contrast agent, were previously determined . The negative control animals were left untreated. The blood, urine and organs (kidneys, liver, spleen and lungs) were collected at various time intervals after the injection of the contrast agent, and R2 was measured on a Bruker Minispec mq60. Several pharmacokinetic parameters (the elimination half-life (Te1/2), the volume of distribution steady state (VDss) and the total clearance (Cltot)) were calculated after measuring the blood concentration of contrast agents [24, 25].
For molecular imaging studies, autoimmune RA was induced in DBA/1 male mice (n = 4 per experimental group) aged 10 weeks (Harlan), by immunization with an emulsion of complete Freund’s adjuvant and type II collagen from chicken sternal cartilage (Sigma-Aldrich) as described ; the healthy control mice were left untreated (n = 4 per experimental group). The mice were distributed into four groups of four mice (two CIA and two healthy groups) and were injected intravenously (i.v.) in the caudal vein at a dose of 100 μmol Fe/kg b.w. with either USPIO-P258 or USPIO-PEG for MRI studies; the mice not injected with contrast agents were used as controls for relaxometric studies. The acquisition of images started immediately after contrast agent injection with RARE or 3D fast imaging with steady-state precession (FISP) sequences.
Signal intensity (SI) values for each time point were measured on RARE images within regions of interest (ROIs) drawn manually at the level of the paw using the ImageJ image analysis software (National Institutes of Health, USA). The standard deviation (SD) of the noise was measured in a region situated out of the animal’s image. SI enhancement (ΔSNR%) was calculated for each sagittal or coronal image according to the following equation:
where SNR = signal-to-noise ratio, SIpost = post-contrast SI, and SIpre = pre-contrast SI.
Technical details are presented in Additional file 1: Methods.
The total area (TA) occupied by black pixels in pre-contrast and 108 minutes post-contrast (thresholded to the pre-contrast level) RARE images of the hind limbs of CIA mice injected with USPIO-P258 was evaluated using the ImageJ software as previously described . Then, the percentage difference of TA (%DTA) in post-contrast as compared to the pre-contrast images was calculated.
Biodistribution, IL-7Rα expression, Perls’-DAB staining of USPIO derivatives on paw samples and Masson’s Trichrome staining; immunofluorescent co-localization of USPIO-P258 with IL-7Rα
At the end of the MRI studies, the mice were killed by a lethal dose of sodium pentobarbital (600 mg/kg b.w., intraperitoneal (i.p.)) and paws were harvested for (immuno)histochemical and biodistribution studies after transcardial perfusion with PBS. Biodistribution in freshly sampled paws was evaluated as described previously, by measuring the R2 on a Bruker Minispec mq60 working at 60 MHz and 37 °C. For (immuno)histochemical studies, paws were fixed in buffered paraformaldehyde and decalcified in Biodec-R (Bio-optica Milano s.p.a) for 8 days before paraffin embedding. IL-7Rα was detected with mouse anti-IL-7Rα monoclonal antibody and peroxidase-conjugated monoclonal anti-mouse antibody produced in goat (both from Sigma-Aldrich) as described previously. USPIO derivatives were detected on paw sections by histochemical analysis, using the Perls’-DAB iron staining protocol [24, 28], while the paw morphology was studied after Masson’s trichrome staining using the Accustain® kit (Sigma-Aldrich) as previously described [24, 25].
USPIO derivatives were also co-localized with IL-7Rα-expressing cells by co-incubating paw sections with rat anti-PEG (Abcam) and mouse anti-IL-7Rα (Sigma-Aldrich) monoclonal antibodies, followed by Texas red-conjugated goat anti-rat and Fluorescein-conjugated horse anti-mouse antibodies (both from Vector Labconsult). The protocols are additionally described in Additional file 1: Methods.
The TA occupied by IL-7Rα staining on the paw sections of CIA mice injected with USPIO-P258 was then quantified on microphotographs using the ImageJ software. The coefficient of correlation r 2 was calculated and the %DTA obtained after analyzing the MR images; these two parameters were also correlated with the severity score of CIA as determined on living mice according to the definitions provided by Brand et al. .
The results are expressed as means ± SD. One-way analysis of variance (ANOVA), performed with SigmaPlot 11.0 software, was applied to compare different experimental groups. For the groups where the equal variance test was not satisfied, the statistical significance was furthermore confirmed after applying the Holm-Sidak and Bonferroni tests. Results were considered statistically significant at p < 0.05.
Identification and characterization of the candidate phage clones
A disulfide constrained heptapeptide phage display library was screened against the extracellular domain of IL-7Rα (E21–D239), which contains an FN type III repeat-like sequence (A131–I231). To remove the potential binders to FN type III domain, the phage library was pre-selected against FN before being screened against IL-7Rα. After four rounds of selection, the affinity of the phage pools towards IL-7Rα was evaluated and compared to that for BSA, used as a blocking agent (Additional file 2: Figure S1A and B). The results show that the second and third rounds of panning present an optimal binding to IL-7Rα, whereas the fourth round had lost its affinity. We therefore isolated 102 clones issued from the second and third rounds of panning, and the K*d against IL-7Rα and FN was determined. Among them, 12 clones (9 from the second round and 3 from the third round) presented the highest affinity for IL-7Rα, with K*d values that ranged from 0.21 nM to 4.15 nM (Additional file 2: Figure S1C and D). The K*d of their binding to FN was variable and ranged between 99.5 μM and 1.98 nM. Based on their Kd FN/Kd IL-7Rα ratio (477, 163 and 6 for the strongest binders), three clones (36/R2, 29/R3 and 37/R2) were selected for supplemental characterization (see Additional file 2: Figure S2 for individual K*d values).
The binding specificity was furthermore validated for these three clones by competing them with IL-7. The IC50 of IL-7 estimated in these conditions provides information on the amount of IL-7 required to dissociate phages from their binding sites. In other words, the higher IC50 value, the stronger binder is the phage clone candidate. We have therefore identified an IC50 value of 2.41 × 10−6 M, 3.98 × 10−8 M and 5.10 × 10−6 M for the competition between IL-7 and the three selected clones (Table 1; Additional file 2: Figure S2).
The peptide sequence of the 12 initial candidate phage clones was deciphered (Additional file 2: Figures S1C and 1D) and their analysis revealed a high frequency of basic (His, Lys) and alcohol (Ser) amino acids, but also of Pro. The alignment of the three best peptide clones with relevant human proteins was searched using the basic alignment search tool BLAST (Table 1), and interesting homologies were found with several serine/threonine-protein kinases, with adhesion molecules and proteins of the extracellular matrix or involved in cytoskeletal organization, cell migration, embryogenesis and inflammation.
Synthesis and in vitro characterization of the candidate molecular imaging peptides
The three candidate peptides were synthesized first as biotinylated derivatives and their K*d for IL-7Rα and FN binding was evaluated (Fig. 1a; Additional file 2: Figure S3); peptide expressed by clone 37/R2 was also synthesized in a linear version by removing the Cys-constraint. Among the four synthesized peptides, P725 (expressed by clone 29/R3; K*d of 0.11 × 10−5 M) and P258 (the linearized peptide expressed by clone 37/R2; K*d of 0.06 × 10−5 M) presented the highest affinity for IL-7Rα, but the ratio K*d FN/K*d IL-7Rα revealed a specific binding to IL-7Rα in the case of P258 (Fig. 1b). This was even higher than that of IL-7 and their K*d IL-7Rα was equivalent. Taken together, these properties emphasize P258 as the best candidate for molecular imaging of RA after its conjugation to an imaging probe. At the same time, the IC50 value of P725 was of 1.64 × 10−5 M (Additional file 2: Figure S3), highlighting it as an optimal competitor of IL-7. However, its equivalent affinity for IL-7Rα and FN renders this peptide inadequate for molecular imaging; the ubiquitous FN expression could generate a high potential background.
Peptides P258 and P725 (Additional file 2: Figure S4A and B) were thus selected for further characterization with the aim of developing in vivo imaging (P258) and blocking (P725) applications. The theoretical biochemical parameters (Table 2) show that peptide P258 has a half-life of 4.4 h as predicted by the N-end rule , while that of P725 is 1.2 h. The N-end rule stipulates that proteasome degradation of proteins within cells depends on the ubiquitin covalent conjugation at the N-terminus residue of the protein to be hydrolyzed. The primary destabilising residues are positively charged (i.e., lysine, arginine, histidine), whereas methionine is a stabilizing residue. The isoelectric point (pI) value and hydrophilic properties, suggested by LogP, LogD, GRAVY and aliphatic index, indicate that both peptides are ionized at physiological pH and may be able to interact with charged residues on the targeted protein.
The two peptides were co-localized with IL-7Rα expressed by ADC-stimulated Jurkat cells (Fig. 1c-h) as proven by the yellow/orange color obtained after overlapping the green staining of peptides (Fig. 1c and d) with the red staining of IL-7Rα (Fig. 1e and f), attesting for their specific interaction. Intensity of the IL-7Rα staining using a monoclonal antibody was decreased by 57 % in the presence of P725, thereby suggesting that this peptide competed with the antibody binding sites on the receptor. Control samples were characterized by very weak staining or no staining (data not shown), which contributed to the validation of specific cell binding of the selected peptides.
In vitro characterization of the functionalized imaging probe USPIO-P258
Peptide P258 was retained for the development of vectorized contrast agents. We confirmed by immunohistochemistry that P258 stains synovial tissue from patients with RA (Additional file 2: Figure S5); the weak staining produced by control peptides P255 and P259 (data not shown) attested for the specific binding of P258 to IL-7R. After grafting to USPIO-258 (Additional file 2: Figure S6A), the K*d of the vectorized contrast agent was 4.9 × 10−6 M for the binding to IL-7Rα (Additional file 2: Figure S6B); with USPIO-P258 there was no binding to the PFBB-coated ELISA plate, proving its specific interaction with the target. With the negative control contrast agent, USPIO-PEG, there was negligible binding to IL-7Rα at high concentrations. The IC50 of USPIO-P258 was of 6.6 × 10−6 M, suggesting that functionalized nanoparticles may have the ability to dislocate IL-7 from IL-7Rα (Additional file 2: Figure S6C). The results of the MTT assay demonstrated that USPIO-P258 did not produce cytotoxic effects at either of the concentrations or times of incubation tested in our experimental conditions (Additional file 2: Figure S6D).
The binding of USPIO-P258 to ADC-stimulated Jurkat cells was evaluated and compared to USPIO-PEG or to NS Jurkat cells. The measurement of iron concentration was significantly higher in ADC samples incubated with USPIO-P258 as compared to NS samples or cells incubated with USPIO-PEG (Fig. 2). At high iron concentrations (i.e., 3 mM corresponding to 2.73 × 10−7 M nanoparticles by assuming approximately 11,000 iron atoms per particle ), USPIO-P258 was also captured by NS cells (p < 0.01 vs. USPIO-PEG), but this may be explained by the constitutive level of IL-7R expression. Iron concentration measured on cell samples was then converted into the number of USPIO-P258 particles bound per cell. We have thereby obtained about 3 × 104 to 7.6 × 104 particles/ADC cell and about 7.3 × 103 to 4.2 × 104 particles/NS cell (Additional file 2: Figure S6E). These estimations are in agreement with the data published by other authors with regard to the number of IL-7R molecules expressed by different types of T cells .
The ability of USPIO-P258 to bind ADC-stimulated cells was validated by MRI and the R2 Norm measurement, but also by immunofluorescence that demonstrated co-localization of USPIO-P258 (but not of USPIO-PEG) with IL-7Rα expressed by ADC cells (Fig. 2; Additional file 2: Figures S7A, B). There was significant correlation between R2 Norm measured by MRI and RRFL measured by immunofluorescence (Additional file 2: Figure S7C), attesting for the specific binding of USPIO-P258; IL-7Rα expression was about six times higher in ADC cells vs. NS cells (Additional file 2: Figure S7D).
In vivo characterization of the functionalized imaging probe USPIO-P258
USPIO-P258 has faster blood clearance as compared to USPIO-PEG, as demonstrated by the Te1/2 (118 minutes vs. 284 minutes for UPIO-PEG) and Cltot (0.595 ml/min/kg vs. 0.116 ml/min/kg for USPIO-PEG). The VDss of USPIO-P258 (0.1 L/kg) is about two times larger than that of USPIO-PEG (0.0475 L/kg), which is confined to the vascular space (Table 3; Additional file 2: Figure S7E). USPIO-P258 was found in urine at concentrations six to eight times higher than USPIO-PEG (Additional file 2: Figure S7F), the highest being observed at 120 minutes post injection.
The biodistribution of USPIO-P258 was evaluated by a bi-exponential treatment of T2 relaxation curves, which provided two relaxation components of the water protons, i.e., a fast component (R2–1) and a slow one (R2–2). USPIO-P258 content in the kidney decreased over time, concomitantly with the increase of urine concentration (Additional file 2: Figures S7G-H). USPIO-PEG also seems to be excreted, at least partly, via the renal system, but its urinary excretion is delayed in comparison with USPIO-P258. The other organs (liver, spleen, lungs) seem only to be transited by USPIO-P258 via the circulatory system, with no significant accumulation (Additional file 2: Figures S8A-F), as opposed to USPIO-PEG, which seems to accumulate in liver and lungs.
For the CIA experiments, only three out of eight mice had signs of severe arthritis defined by a score of 4 according to the method of Brand et al. . For the MRI studies, CIA and healthy mice were injected with either USPIO-P258 or USPIO-PEG and the limbs were imaged by MRI at 7 T. Both RARE (raw images in Additional file 2: Figure S9; color overlay in Fig. 3) and FISP (Additional file 2: Figure S10) MRI sequences demonstrated significant negative contrast in the hind limbs of CIA mice, which was not equivalent to any of the negative controls. The negative contrast was evident from the first 12 minutes post injection and persisted until the end of the imaging session (about 2 h) (Fig. 4a-b). The tissue contrasted by USPIO-P258 corresponds to the joints between the tarsal, metatarsal and phalangeal bones and the associated soft tissue. Considering the small size of these bones in mice, it was not possible to distinguish their individual constituents (synovium, cartilage, subchondral bone) by MRI; they appeared as a continuous black trait on the negatively contrasted images of the paw. In addition, the susceptibility effect of iron oxide nanoparticles also contributes to this continuous pattern of contrast. Negative contrast was also observed at the knee.
The ΔSNR% measured on sagittal and coronal RARE images (Fig. 4a-b) confirms the negative contrast produced by USPIO-P258 in hind limbs of CIA mice, where it decreased to about −45 % by 12–25 minutes post injection, and remained constant until 60–70 minutes (around −40 %); at the end of the imaging session (about 2 h), ΔSNR% increased to around −30 %. USPIO-PEG injected into CIA mice produced a decrease to −20 % to −25 % of ΔSNR% 12–25 minutes post contrast, but the negative contrast increased to −13 % to −11 % by the end of the imaging session. The ΔSNR% values measured in healthy mice injected with USPIO-P258 or USPIO-PEG were close to the pre-contrast level and ranged between −5 % and −11 %. These results seem to confirm the RA diagnostic potential of USPIO-P258, probably via specific binding to IL-7Rα.
The biodistribution of contrast agents in the limbs sampled from the mice at the end of the imaging session was evaluated by relaxometry (Fig. 4c-d). The data demonstrated an important accumulation of USPIO-P258 in the limbs of mice with RA as compared to healthy mice (p < 0.01). A significant difference (p < 0.05) was also observed in comparison with CIA mice injected with USPIO-PEG, confirming the specific targeting of IL-7Rα by USPIO-P258. The results obtained in healthy mice injected with contrast agents were not significantly different from those observed in the control mice not receiving contrast agents.
The expression of IL-7Rα in the hind limbs of CIA mice subjected to MRI studies was confirmed by immunohistochemical analysis, whereas the Perls’-DAB staining was used to detect contrast agents in the limb tissues (Fig. 5). The connective tissue and different cell types in CIA or healthy tissues were observed using Masson’s Trichrome staining. A prominent leucocyte invasion was observed in the cartilage and synovial tissue of CIA mice compared to healthy mice, which co-localized with high IL-7Rα expression and iron staining when USPIO-P258 was injected. IL-7Rα and USPIO derivatives (USPIO-P258 or USPIO-PEG) were additionally co-localized by immunofluorescence on the same paw section (Fig. 6), USPIO being detected with an anti-PEG antibody. PEG is used both as a stealth coating material and as a linker between P258 and USPIO (Additional file 2: Figure S6A). These results confirm the very good co-localization of IL-7Rα with USPIO-P258 but not with USPIO-PEG, thereby corroborating the specific targeting.
The %DTA in post-contrast images of CIA mice injected with USPIO-P258 and the TA occupied by IL-7Rα staining on the paw sections of the same mice were analyzed using ImageJ software and the results are presented in Fig. 7a. There was strong positive correlation between the mean values of %DTA and those of TA for IL-7Rα staining (r 2 = 0.952), and between the severity score of CIA and %DTA (r 2 = 0.877) or TA for IL-7Rα staining (r 2 = 0.818) (Fig. 7b).
In vitro characterization of the blocking activity of P725
Jak/STAT is one of the main signaling pathways that are activated by IL-7 upon binding to IL-7Rα . Aiming to validate the ability of P725 to prevent IL-7 binding to its receptor and the triggering of Jak/STAT signaling cascade, a competition experiment was performed by treating ADC-stimulated Jurkat cells with IL-7 and P725; anti-IL-7Rα antibody was used as a positive control. The phosphorylation of Tyr694 in STAT-5 was evaluated by immunofluorescence in treated cells. There was an increase of 424 % increase in phospho-STAT-5 in IL-7-treated cells as compared to ADC-treated controls, which attested for its activation. Anti-IL-7Rα antibody (p < 0.01) and P725 (p < 0.01) prevented IL-7 binding and STAT-5 activation, demonstrating a pharmacological effect associated with its IL-7 competing activity (Additional file 2: Figures S11A and B).
IL-7R is internalized subsequent to IL-7 binding via clathrin-dependent endocytosis, followed by its recycling or degradation within lysosomes. We therefore repeated the competition experiment with the aim of quantifying the lysosome content of Jurkat cells and thus deduce the outcome of IL-7R when its binding to IL-7 is prevented by P725 (Additional file 2: Figure S12). The effects produced by anti-IL-7Rα antibody and P725 followed the same pattern as that of phospho-STAT-5. IL-7 induced a significant increase in lysosome content (398 % vs. ADC-treated controls), suggesting endocytosis and lysosome degradation of IL-7R. The lysosome content of Jurkat cells significantly diminished after treatment with anti-IL-7Rα antibody (p < 0.05) or P725 (p < 0.05), suggesting that both competitors prevent IL-7R endocytosis followed by lysosome degradation induced by IL-7. This phenomenon may explain the STAT-5 inactivation produced by both competitors.
The clinical imaging methods currently used for RA diagnosis and monitoring (i.e., radiography, computed tomography, MRI and ultrasound) provide information on bone erosions and joint space narrowing [20, 21]; however, no information is obtained on the cellular and molecular mechanisms of the disease that precede the development of destructive lesions, which sometimes trigger serious debility in less than 2 years in 10 % of cases. Most imaging probes used for RA diagnosis and monitoring are unspecific, although several classic or novel targeted imaging agents have been assessed, such as 18F-fluorodeoxyglucose (18F-FDG), [11C]Choline, (R)-[11C]PK11195 and other translocator protein (TSPO)-targeted radiotracers, [67Ga]Citrate, [99mTc]- and [111In] human immunoglobulin G (HIG), [99mTc]- and [111In]anti-E-selectin, [99mTc]- and [111In]Octreotide, [99mTc]Anti-TNF-α and [99mTc]Annexin V, etc. [21–23]. Among them, only 18F-FDG, TSPO-targeted radiotracers (e.g., 11CPBR28, 18F-GE-180), the αvβ3-specific imaging probe 68Ga-BNOTA-PRGD2 and the PET probe 18F-FHBG employed for the imaging of reporter genes, are currently undergoing clinical trials according to the US National Institutes of Health . Examples of new imaging tracers include 99mTc-labeled derivative of octreotide peptide employed to image somatostatin receptor expressed by T lymphocytes , and several radiotracers used to monitor therapy response in human or experimental arthritis, such as 99mTc-NTP 15–5 targeted to proteoglycans in the RA joints , 111In-RGD2 (αvβ3-targeted), 111In-anti-fibroblast activation protein antibody and 111In-antimurine macrophage antibody . Therefore, there is active research to meet the increasing demand of imaging methods and probes able to provide precocious and reliable information on the clinical outcome, pathophysiological process, the disease severity and location, and the disease response to novel molecular therapies.
The role of IL-7R and IL-7 in the pathogenesis of RA is well-documented. Both molecules are expressed in RA synovial tissue and blockade of the IL-7/IL-7R axis in CIA results in significant clinical improvement. In addition, IL-7Rα was recently identified as a diagnostic marker in early RA, and a marker of severity and poor response to therapy in early and established disease. Our attempts to develop in vivo IL-7Rα imaging tracers are based on these observations, and fit in a novel approach to the taxonomy of inflammatory joint disorders, in which diagnostic and therapeutic decisions are based on the identification of specific molecular pathways, rather than broad clinical diagnostic categories. Thus, we identified several IL-7Rα-specific heptapeptides, which are potential vectors for RA-dedicated imaging probes. Some of them are putative therapeutic agents that work by blocking IL-7 ligation to IL-7R. To the best of our knowledge, no other IL-7Rα-targeted small molecule has been discovered and exploited in the framework of RA diagnosis and treatment.
During the screening of the randomized cyclic heptapeptide phage display library, it was observed that most clones had high affinity against FN type III-like domain of IL-7Rα (A131-I231), suggesting its involvement in ligand binding. Indeed, specialized literature has shown that 5 of the 12 amino acids (S51, F99, L100, L101, I102, K104, D122, H154, K157, Y159, V160, H211) are involved in IL-7 ligation . As a consequence, excessive preselection against FN has led to a decline in phage pool affinity for IL-7Rα during the third and particularly the fourth round of panning. The peptide sequence of the 12 phage clones selected from the second and the third rounds of panning presented a high frequency of basic (His, Lys) and alcohol (Ser) amino acids, but also a Pro repetition. The first three amino acids are potentially involved in IL-7Rα binding based on the proposed model , whereas Pro can induce 20° distortions in the axis of an alpha helix, which suggests that peptides can present a certain 3D conformation. The three best peptide clones (C-PHPQRPA-C, C-KIMKSMP-C and C-ASACPPH-C) characterized by the highest specific affinity against IL-7Rα have shown interesting homologies with molecules involved in signal transduction, cell adhesion, extracellular matrix, cytoskeletal organization, cell migration, embryogenesis and inflammation, proving that their selection was not accidental.
Before synthesis, peptide C-PHPQRPA-C presented the highest binding specificity, whereas peptide C-ASACPPH-C was the weakest candidate. However, after synthesis, peptide C-PHPQRPA-C (encoded as P722) had lost its affinity against IL-7Rα, displaying equivalent binding to FN. Peptide C-KIMKSMP-C (encoded as P725) had better affinity for FN than for IL-7Rα, but its μM Kd indicated stronger binding than that of P722. To our surprise, the highest specific binding to IL-7Rα was observed in the case of peptide C-ASACPPH-C (encoded as P726), which thus became the most promising candidate for diagnostic applications. Aiming to eventually improve its affinity constant, the peptide was synthesized in a linear version (encoded as P258), checking in this way the necessity of Cys-constraint. This chemical strategy has indeed enhanced its affinity in the order of nanomolar and improved its specificity against IL-7Rα. The linear peptides present a more flexible spatial conformation, with functional groups optimally exposed for a chemical interaction with the targeted biomarker .
One can conclude that peptide P258 presents a chemical interaction with IL-7Rα, the conformational compatibility (imposed by Cys-constraint) not being a prerequisite. Peptide P258 was thus subsequently used to functionalize a MRI contrast agent such as USPIO (USPIO-P258). This reversal of the affinity parameters of the three candidate peptides after their synthesis is explained by the monovalent exposure to the target, after being presented in a pentavalent display on the phage entity. It is very well-known that pentavalent presentation is responsible for an avidity effect that may facilitate the binding of certain peptides to their target.
In our experimental conditions, IL-7 was characterized by a Kd (1.7 × 10−7 M) close to that of P258, being inferior to the value reported previously (i.e., 2 × 10−10 M against the high-affinity IL-7R and 10−8 M against the low-affinity IL-7R) . The truncated recombinant IL-7Rα protein (241 amino acids instead of 459 amino acids), removed from its cellular environment, may be responsible for the lower affinity constant observed in our experimental conditions. In addition, two antibodies were used to detect IL-7, which means that additional rinsing steps may contribute to extensive protein removal and lower apparent affinity. However, an interesting observation was that P725 displayed competitive abilities against IL-7, which highlighted its role as a potential therapeutic agent by blocking IL-7 binding to its receptor.
With regard to imaging applications of our IL-7Rα-targeted peptide, USPIO-P258 had good ability to distinguish stimulated from non-stimulated Jurkat cells and its binding to IL-7Rα co-localized with anti-IL-7Rα antibody, confirming its specificity. The blood clearance of USPIO-P258 is much faster than that of USPIO-PEG, and its elimination is likely to mainly occur via a renal pathway. In addition, USPIO-P258 does not seem to accumulate in the main organs, which are simply transited via the blood stream. We have previously observed [24, 25] that peptide grafting to USPIO is responsible for enhanced blood clearance, an enlarged VDss and increased urinary excretion, probably due to diminished PEG grafting that is partly replaced by peptides on the surface of nanoparticles. Moreover, these biodistribution and pharmacokinetic properties are amplified by peptides with a hydrophilic character.
USPIO-P258 produced a significant negative contrast in the paws of CIA mice, which was not equivalent to any of the control mice. The negative contrast corresponded to the tarsal, metatarsal and phalangeal joints, and persisted for about 2 hours post injection. The contrast agent accumulation in the hind limbs of CIA mice was confirmed by relaxometry and histochemical analysis at the end of the imaging session. The contrast observed at long image acquisition times suggests the specific binding to the targeted receptor, as most of the contrast agent has been cleared from the blood. On histological examination, USPIO-P258 co-localized with IL-7Rα expression in the paws of CIA mice, attesting for its specific accumulation at this level. A non-specific accumulation of USPIO-PEG was also observed in the diseased paws, probably as a result of its phagocytosis by the local macrophages, but its capture was less important as compared to USPIO-P258. Taken together, these results confirm the imaging ability of USPIO-P258 as an IL-7Rα imaging marker, the diagnostic faculty being furthermore confirmed by the high positive correlation between its accumulation in the diseased paws, the IL-7Rα expression and the disease severity.
One of the most important signaling pathways that are activated by IL-7 ligation to its receptor is Jak/STAT, which triggers the phosphorylation of cytoplasmic tyrosine kinases associated with IL-7Rα and the common γ-chain, respectively. Once activated, Jak1 can phosphorylate the Tyr449 residue of IL-7Rα, which recruits the transcription factor STAT5 (a heterodimer comprising STAT5a and STAT5b) that is itself tyrosine-phosphorylated by Jak. Phosphorylated STAT5 can dimerize and translocate to the nucleus, where it regulates the transcription of several genes involved in T cell survival and proliferation [2–4]. The inhibition of IL-7 engagement with its receptor by a specific competitor may have potential therapeutic effects in various inflammatory conditions such as RA. The competitive character of P725 was thus confirmed by immunofluorescence, using ADC-stimulated Jurkat cells as a model. P725 inhibited IL-7-induced STAT5 activation by 82 %, which was similar to that produced by anti-IL-7Rα antibody (86 %).
It has been shown that IL-7Rα is rapidly inactivated by lysosome and proteasome-dependent degradation subsequent to its endocytosis triggered by IL-7 activation. In fact, IL-7 signal transduction requires clathrin-dependent endocytosis of IL-7Rα followed by its degradation by proteolysis . In order to check whether STAT5 inactivation induced by P725 treatment is associated with a diminished IL-7Rα endocytosis, we have indirectly measured the lysosome content of Jurkat cells in the same experimental conditions as for STAT5. Our results confirm the increased lysosome content of Jurkat cells stimulated by IL-7, and suggest that P725 ligation to IL-7Rα blocks IL-7 binding and inhibits the endocytosis and lysosome-dependent degradation of IL-7Rα.
In the present work, we designed IL-7Rα-targeted peptides. The design of cytokine agonists and antagonists of small molecular size is of notable pharmaceutical interest in RA  and our work integrates with this general optic. The two IL-7Rα-targeted heptapeptides are hydrophilic and ionized at physiological pH, the blocking one being cyclic (P725), whereas the imaging peptide is linear (P258). The potential blocking effect of P725 was validated in vitro, by preventing STAT5 activation induced by IL-7. Considering its equivalent affinity for IL-7Rα and FN, P725 is not a suitable candidate for molecular imaging applications due to the high potential background generated by the ubiquitously expressed FN. P258 grafted to USPIO produced strong negative contrast in experimental arthritis, even at two hours post-injection when the blood concentration of the imaging probe was very low (18 % from C0). The co-localization of USPIO-P258 with IL-7Rα-expressing cells in CIA synovitis demonstrates its specific binding to the targeted receptor. In CIA conditions, USPIO-P258 is able to discriminate the level of IL-7R expression and the disease severity.
basic local alignment search tool
bovine serum albumin
- Cltot :
difference in total area
enzyme-linked immunosorbent assay
extracellular signal-related kinase
fast imaging with steady-state precession
- IC50 :
half maximal inhibitory concentration
interleukin-7 receptor alpha
Janus kinase 1
- K*d :
apparent dissociation constant
mitogen activated protein kinase
magnetic resonance imaging
phosphate-buffered saline supplemented with Tween-20
photon correlation spectroscopy
protein-free blocking buffer
- r2 :
- R2 :
transverse relaxation rate
receptor activator of nuclear factor-κB
receptor activator of nuclear factor-κB ligand
rapid acquisition with relaxation enhancement
regions of interest
relative ratio of fluorescent labeling
signal transducer and activator of transcription 5
- T2 :
transverse relaxation time
- Te1/2 :
transforming growth factor-β
tumor necrosis factor-alpha
ultra-small superparamagnetic particles of iron oxide
volume of distribution steady state
Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094–108.
McElroy CA, Holland PJ, Zhao P, Lim JM, Wells L, Eisenstein E, Walsh ST. Structural reorganization of the interleukin-7 signaling complex. Proc Natl Acad Sci U S A. 2012;109:2503–8.
Johnson SE, Shah N, Bajer AA, LeBien TW. IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors. J Immunol. 2008;180:8109–17.
Giliani S, Mori L, de Saint BG, Le Deist F, Rodriguez-Perez C, Forino C, Mazzolari E, Dupuis S, Elhasid R, Kessel A, Galambrun C, Gil J, Fischer A, Etzioni A, Notarangelo LD. Interleukin-7 receptor alpha (IL-7R alpha) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol Rev. 2005;203:110–26.
Okamoto K, Takayanagi H. Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther. 2011;13:219.
Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJU, Houssiau FA, Lauwerys B. Identification of distinct gene expression profiles in systemic lupus erythematosus. Arthritis Rheum. 2007;56:1579–88.
Lauwerys BR, Hernández-Lobato D, Gramme P, Ducreux J, Dessy A, Focant I, Ambroise J, Bearzatto B, Nzeusseu Toukap A, Van den Eynde BJ, Elewaut D, Gala JL, Durez P, Houssiau FA, Helleputte T, Dupont P. Heterogeneity of synovial molecular patterns in patients with arthritis. PLoS One. 2015;10:e0122104.
Gonzalez-Quintial R, Lawson BR, Scatizzi JC, Craft J, Kono DH, Baccala R, Theofilopoulos AN. Systemic autoimmunity and lymphoproliferation are associated with excess IL-7 and inhibited by IL-7Rα blockade. PLoS ONE. 2011;6:e27528.
Pickens SR, Chamberlain ND, Volin MV, Pope RM, Talarico NE, Mandelin 2nd AM, Shahrara S. Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2011;63:2884–93.
Moret FM, Badot V, Lauwerys BR, van Roon JA. Intraarticular soluble interleukin-7 [corrected] receptor levels are increased in patients with rheumatoid arthritis and correlate with local mediators of inflammation: comment on the article by Pickens et al. Arthritis Rheum. 2012;64:594–5. author reply 595–596.
Hartgring SA, van Roon JA, Wenting-van Wijk M, Jacobs KM, Jahangier ZN, Willis CR, Bijlsma JW, Lafeber FP. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum. 2009;60:2595–605.
Lundström W, Highfill S, Walsh ST, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mackall CL. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A. 2013;110:E1761–70.
Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Van den Eynde BJ, Durez P, Houssiau FA, Lauwerys BR. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R57.
Badot V, Durez P, Van den Eynde BJ, Nzeusseu-Toukap A, Houssiau FA, Lauwerys BR. Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines. J Cell Mol Med. 2011;15:2335–42.
Hartgring SA, Willis CR, Bijlsma JW, Lafeber FP, van Roon JA. Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther. 2012;14:R137.
Chen Z, Kim SJ, Chamberlain ND, Pickens SR, Volin MV, Volkov S, Arami S, Christman JW, Prabhakar BS, Swedler W, Mehta A, Sweiss N, Shahrara S. The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J Immunol. 2013;190:5256–66.
Hartgring SA, Willis CR, Alcorn D, Nelson LJ, Bijlsma JW, Lafeber FP, van Roon JA. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 2010;62:2716–25.
Badot V, Luijten RK, van Roon JA, Depresseux G, Aydin S, Van den Eynde BJ, Houssiau FA, Lauwerys BR. Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72:453–6.
Hillen MR, Blokland SL, Risselada AP, Bikker A, Lauwerys BR, Kruize AA, Radstake TR, van Roon JA. High soluble IL-7 receptor expression in Sjögren’s syndrome identifies patients with increased immunopathology and dryness. Ann Rheum Dis. 2016;75(9):1735–6.
Sizova L. Imaging methods of joint damage in early rheumatoid arthritis. Curr Rheumatol Rev. 2015. [Epub ahead of print]
Sudoł-Szopińska I, Cwikła JB. Current imaging techniques in rheumatology: MRI, scintigraphy and PET. Pol J Radiol. 2013;78:48–56.
Put S, Westhovens R, Lahoutte T, Matthys P. Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques. Arthritis Res Ther. 2014;16:208.
Zeman MN, Scott PJ. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging. 2012;2:174–220.
Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, Port M, Corot C, Vander Elst L, Muller RN. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol. 2012;32:e36–48.
Ansciaux E, Burtea C, Laurent S, Crombez D, Nonclercq D, Vander Elst L, Muller RN. In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood–brain barrier: toward earlier diagnosis of Alzheimer's disease by molecular imaging. Contrast Media Mol Imaging. 2015;10:211–24.
Kim HR, Hwang KA, Kim KC, Kang I. Down-regulation of IL-7R expression in human T cells via DNA methylation. J Immunol. 2007;178:5473–9.
Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007;2:1269–75.
Burtea C, Laurent S, Crombez D, Delcambre S, Sermeus C, Millard I, Rorive S, Flamez D, Beckers MC, Salmon I, Vander Elst L, Eizirik DL, Muller RN. Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)γa as a highly specific biomarker of pancreatic beta cells. Contrast Media Mol Imaging. 2015;10:398–412.
Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science. 1986;234:179–86.
Vudattu NK, Kuhlmann-Berenzon S, Khademi M, Seyfert V, Olsson T, Maeurer MJ. Increased numbers of IL-7 receptor molecules on CD4 + CD25-CD107a + T-cells in patients with autoimmune diseases affecting the central nervous system. PLoS One. 2009;4:e6534.
Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood. 2010;115:3269–77.
ClinicalTrials.gov, A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ (2016). Accessed 11 July 2016.
Anzola-Fuentes LK, Chianelli M, Galli F, Glaudemans AW, Martin Martin L, Todino V, Migliore A, Signore A. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren's syndrome treated with Infliximab: a pilot study. EJNMMI Res. 2016;6:49.
Khairnar A, Marchand F, Vidal A, Etienne M, Miladi I, Auzeloux P, Cachin F, Eschalier A, Chezal JM, Ardid D, Miot-Noirault E. 99mTc-NTP 15–5 imaging for cartilage involvement in experimental rheumatoid arthritis: comparison with routinely used molecular imaging methods and sensitivity to chronic nonsteroidal antiinflammatory drug treatment. J Nucl Med. 2015;56:798–804.
Terry SY, Koenders MI, Franssen GM, Nayak TK, Freimoser-Grundschober A, Klein C, Oyen WJ, Boerman OC, Laverman P. Monitoring therapy response of experimental arthritis with radiolabeled tracers targeting fibroblasts, macrophages, or integrin αvβ3. J Nucl Med. 2016;57:467–72.
Kroemer RT, Richards WG. Homology modeling study of the human interleukin-7 receptor complex. Protein Eng. 1996;9:1135–42.
Roxin Á, Zheng G. Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides. Future Med Chem. 2012;4:1601–18.
Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J Exp Med. 1997;186:325–30.
This work was supported by the project KeyMarker “Pôles de compétitivité BioWin” of the Walloon Region, Belgium (01/11/2006-31/03/2010). The Walloon Region (program First spin-off), FNRS (Fond National de la Recherche Scientifique), and ARC Programs of the French Community of Belgium are also gratefully acknowledged. The authors thank the Center for Microscopy and Molecular Imaging (CMMI, supported by the European Regional Development Fund and the Federation Wallonia Brussels).
Study concept and design: CB, SL, TS and M-CB. Acquisition of data: CB, SL, TS, DF, AD, SS, M-CB and SR. Analysis and interpretation of data: CB, SL, TS, DF, AD, SS, M-CB, SR and BRL. Statistical analysis: CB, TS and DF. All authors were involved in drafting the manuscript, and in critical revision of the manuscript and approval of the final version. CB, M-CB, IS, BRL, LVE and RNM obtained funding.
The authors declare that they have no competing interests.
About this article
Cite this article
Burtea, C., Laurent, S., Sanli, T. et al. Screening for peptides targeted to IL-7Rα for molecular imaging of rheumatoid arthritis synovium. Arthritis Res Ther 18, 230 (2016). https://doi.org/10.1186/s13075-016-1133-8
- Rheumatoid arthritis
- IL-7 receptor
- Ultra-small superparamagnetic particles of iron oxide
- Molecular imaging
- Phage display